CD86 and neoplasm: Interestingly, unlike in the case of macrophages, the combination CpG-STAT3ASO/anti-PD-1 treatment but not CpG-STAT3ASO or anti-PD-1 alone led to a significant recruitment of activated (MHC-IIHI and CD86+ or CD80+) DCs into tumor-draining lymph nodes (Figure 6D and Supplementary Figure S5).